Evolent Health, Inc. Stock

Equities

EVH

US30050B1017

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 12:20:03 2024-04-23 pm EDT 5-day change 1st Jan Change
30.56 USD +2.36% Intraday chart for Evolent Health, Inc. +0.96% -7.81%
Sales 2024 * 2.47B Sales 2025 * 2.86B Capitalization 3.4B
Net income 2024 * 19M Net income 2025 * 69M EV / Sales 2024 * 1.54 x
Net Debt 2024 * 391M Net Debt 2025 * 272M EV / Sales 2025 * 1.28 x
P/E ratio 2024 *
1,168 x
P/E ratio 2025 *
62 x
Employees 4,700
Yield 2024 *
0.9%
Yield 2025 *
0.84%
Free-Float 94.57%
More Fundamentals * Assessed data
Dynamic Chart
Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target MT
Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating MT
JPMorgan Trims Price Target on Evolent Health to $52 From $53, Maintains Overweight Rating MT
Transcript : Evolent Health, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Canaccord Genuity Cuts Price Target on Evolent Health to $45 From $47, Maintains Buy Rating MT
Evolent Health Q4 Adjusted Income, Revenue Rise; Q1, 2024 Revenue Guidance Set; Shares Jump After Hours MT
Transcript : Evolent Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (EVH) EVOLENT HEALTH Reports Q4 EPS $0.23, vs. Street Est of $0.15 MT
Earnings Flash (EVH) EVOLENT HEALTH Posts Q4 Revenue $556.1M, vs. Street Est of $542.9M MT
Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024 CI
Evolent Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Evolent Health, Inc. Announces Board Changes CI
Transcript : Evolent Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:45 PM
JMP Securities Initiates Evolent Health With Market Outperform Rating, Price Target is $37 MT
Evolent Health Plans $350 Million Convertible Senior Notes Offering; Shares Fall MT
More news
1 day+0.08%
1 week-1.45%
Current month-8.94%
1 month-7.90%
3 months-3.46%
6 months+11.13%
Current year-9.60%
More quotes
1 week
29.06
Extreme 29.06
30.51
1 month
29.06
Extreme 29.06
33.31
Current year
28.82
Extreme 28.82
35.00
1 year
23.33
Extreme 23.33
36.70
3 years
17.62
Extreme 17.62
39.78
5 years
3.50
Extreme 3.5
39.78
10 years
3.50
Extreme 3.5
39.78
More quotes
Managers TitleAgeSince
Founder 45 11-07-31
President - 22-09-14
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 70 20-01-31
Director/Board Member 59 23-06-07
Chairman 74 15-10-31
More insiders
Date Price Change Volume
24-04-23 30.51 +2.18% 263 547
24-04-22 29.86 +1.19% 646,303
24-04-19 29.51 -0.37% 734,826
24-04-18 29.62 -0.07% 827,175
24-04-17 29.64 -1.72% 710,339

Delayed Quote Nyse, April 22, 2024 at 04:00 pm EDT

More quotes
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advance care planning services as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
29.86 USD
Average target price
44.86 USD
Spread / Average Target
+50.22%
Consensus